Hematology Xagena
In patients with transplant-ineligible newly diagnosed multiple myeloma ( NDMM ), Daratumumab ( Darzalex ) has reduced the risk of disease progression or death by 44% in MAIA ( Daratumumab / Lenalidom ...
A phase 1-2 study evaluated Brentuximab vedotin ( Adcetris ) combined with Nivolumab ( Opdivo ) as first salvage therapy in patients with relapsed/refractory ( r/r ) classical Hodgkin lymphoma ( cHL ...
Myelofibrosis symptoms compromise health-related quality of life ( HRQoL ). Ruxolitinib can reduce myelofibrosis symptom severity, but many patients discontinue Ruxolitinib due to loss of response or ...
Low-density lipoprotein ( LDL ) receptor-related protein-associated protein 1 ( LRPAP1 ) had been identified by B-cell receptor ( BCR ) expression cloning and subsequent protein array screening as a f ...
Tafasitamab, an Fc-modified, humanized, anti-CD19 monoclonal antibody, combined with the immunomodulatory drug Lenalidomide ( Revlimid ), was clinically active with a good tolerability profile in the ...
Low-density lipoprotein ( LDL ) receptor-related protein-associated protein 1 ( LRPAP1 ) had been identified by B-cell receptor ( BCR ) expression cloning and subsequent protein array screening as a f ...
Early recognition of Ph-like acute lymphoblastic leukemia cases could impact on the management and outcome of this subset of B-lineage ALL. To assess the prognostic value of the Ph-like status in ...
Mediastinal gray zone lymphoma ( MGZL ) is a rare form of non-Hodgkin lymphoma ( NHL ) with intermediate features between classical Hodgkin lymphoma ( cHL ) and primary mediastinal B-cell lymphoma ( P ...
Bortezomib, Lenalidomide, Dexamethasone plus transplant is a standard of care for eligible multiple myeloma patients. As responses can deepen with time, regimens with longer and more potent inductio ...
Daratumumab, a human IgGκ monoclonal antibody targeting CD38, is approved as monotherapy and in combination with standard-of-care regimens for relapsed / refractory multiple myeloma and newly diagnose ...
Ibrutinib ( Imbruvica ) inhibits chronic lymphocytic leukemia ( CLL ) proliferation and effects prolonged remission without eradicating disease. Obinutuzumab ( Gazyvaro ) is an anti-CD20 monoclonal ...
Patients with relapsed or refractory ( R/R ) diffuse large B-cell lymphoma ( DLBCL ) or mantle cell lymphoma ( MCL ) have a poor prognosis and many do not have long-term disease control with salvage t ...
Renal impairment, a frequent complication and poor prognostic factor in relapsed / refractory multiple myeloma ( RRMM ), often leads to poor tolerability of standard regimens. Researchers have rep ...
Polatuzumab vedotin ( Polivy ) combined with Rituximab ( MabThera ) has demonstrated activity and tolerability in a phase II trial of patients with relapsed / refractory ( R/R ) diffuse large B-cell l ...
Venetoclax ( Venclexta ) in newly-diagnosed AML patients who are ineligible for intensive chemotherapy is supported by data from a series of trials including two phase 3 trials, VIALE-A ( M15-656 ) an ...
